# Alladapt Immunotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alladapt-immunotherapeutics

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.alladapt.com
- Total disclosed funding: $178M
- Latest round: Series D (Jun 22, 2022)
- Investors on record: 7

## About

Alladapt Immunotherapeutics, based in the US, focuses on developing innovative immunotherapeutic solutions aimed at treating various allergic conditions through advanced technology.Founded in 2018 in Menlo Park, California, Alladapt Immunotherapeutics, Inc. is dedicated to creating breakthrough therapies for allergy treatment. The company has raised a total of USD 119.00 mn across multiple funding rounds, with the latest being a VENTURE DEBT round of USD 50.00 mn from Hercules Capital on August 30, 2022. CEO and Founder Ashley Dombkowski leads the firm, leveraging her expertise in the biotech industry.Alladapt Immunotherapeutics specializes in immunotherapeutic products aimed at treating allergic conditions. Their key offerings include novel therapies designed to modulate the immune system's response to allergens, providing a potential solution for patients with allergic diseases. The company primarily targets the healthcare sector, focusing on enhancing the quality of life for individuals suffering from allergies through innovative treatment methods that promise effective long-term management.The company generates its revenue through the commercialization of its immunotherapy products, which are sold directly to healthcare providers and institutions. By establishing partnerships with key stakeholders in the healthcare industry, Alladapt aims to facilitate wider accessibility to its therapies, driving revenue growth as demand for effective allergy treatments increases. Their strategic approach to market engagement ensures a sustainable revenue model as they expand their product offerings.Alladapt Immunotherapeutics plans to utilize the USD 50.00 mn raised in VENTURE DEBT funding to accelerate the development of its immunotherapeutic products, with a focus on expanding its product pipeline. The company aims to introduce new therapies within the next 18 months, targeting specific allergic conditions that currently have limited treatment options. Additionally, they are exploring opportunities for expansion into international markets, particularly Europe and Asia, by 2024, to broaden their reach and impact in the global healthcare landscape.

## Funding rounds

- Series D, Jun 22, 2022, $119M — West River Group, Gurnet Point Capital, Novartis, Red Tree Venture Capital, Patient Square Capital, AllerFund, Enavate Sciences
- Series C, Dec 31, 2019, $59M — Gurnet Point Capital

## Investors

- Gurnet Point Capital (https://capitalatlas.ai/funds/gurnet-point-capital) — Series C, Series D
- West River Group — Series D
- Novartis — Series D
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series D
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series D
- AllerFund (https://capitalatlas.ai/funds/allerfund) — Series D
- Enavate Sciences — Series D